Please login to the form below

Not currently logged in
Email:
Password:

UCB forms alliance with Harvard

UCB is to collaborate with Harvard University on the research of therapies for conditions related to the central nervous system and immunology

UCB is to collaborate with Harvard University on the research of therapies for conditions related to the central nervous system and immunology.

The Belgium-based biopharma company will provide Harvard scientists with up to $6m over two years to fund innovative research projects in the specialist areas.

Expertise in antibody generation and medicinal chemistry will also be provided by UCB.

The company said it aims to 'capitalise' on external scientific research, with the collaboration intended as a 'two-way exchange of knowledge and expertise' to help develop new drugs, according to Ismail Kola, president of UCB NewMedicines.

The first project to receive funding from the collaboration is a study looking at developing antibodies against a specific target with implications for diabetes and metabolic disorders. It is led by Professor Gökhan S Hotamisligil, Department of Genetics and Complex Diseases, Harvard School of Public Health.

Regular meetings will be held between the university and UCB to decide what future projects to fund.

Isaac T Kohlberg, chief technology development officer at Harvard, was positive about the potential benefits for the university from the collaboration: "It exemplifies Harvard's growing commitment to collaborate with industry in creative ways that will advance the boundaries of translational research, thereby realising our core mission to serve the public interest."

The announcement follows a collaboration between sanofi-aventis and Harvard focusing on translational biomedical research in therapeutic areas, including cancer and diabetes.

28th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics